Arbutus to receive $20 million in gross proceeds before advisory fees while retaining significant downstream economics Runway extended with non-dilutive capital WARMINSTER, Pa., July 02, 2019 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading… Read More
VANCOUVER, British Columbia and MENLO PARK, Calif., June 27, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization… Read More
VANCOUVER, British Columbia and MENLO PARK, Calif., June 25, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of… Read More
June 13, 2019 (Ottawa) The Stem Cell Network is pleased to launch a new national research funding competition comprised of four translational research programs in stem cell and regenerative medicine. The… Read More
– AB-729 is a subcutaneously-administered RNAi agent targeting HBV replication and HBsAg antigen production – Supports corporate objective to combine AB-729 with AB-506, Arbutus’ proprietary oral capsid inhibitor WARMINSTER, Pa., June… Read More
